Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS" or the "Company"), the international specialty pharma company, announces that in order to satisfy institutional demand, it has amended the terms of the lock-up arrangements with the ex-shareholders of Advanced Bio-Technologies Inc.
11,478,136 (57%) of the 19,990,000 ordinary shares issued as consideration have now been released four months post completion, as opposed to six months post completion as originally envisaged, with 10,000,000 of these being placed with investors. The remaining 45% remain subject to the same lock-up timetable with half of these being released on 15 December 2012 (the one year anniversary of the acquisition's completion) and the balance on 30 June 2013.
Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.